Skip to search formSkip to main contentSkip to account menu

Rilpivirine

Known as: 4-((4-((4-((1E)-2-Cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile, 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile, Rilpivirine [Chemical/Ingredient] 
A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV… 
National Institutes of Health

Related topics

Related topics

16 relations

Broader (2)

Anti-HIV AgentsReverse Transcriptase Inhibitors

Narrower (4)

CompleraR278474TMC 278rilpivirine hydrochloride
HIV InfectionsIn BloodRilpivirine 25 MG Oral Tablet [Edurant]Rilpivirine:Susc:Pt:Isolate:OrdQn:Phenotyping

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study
P Gantner, L Cuzin, C Allavena, A Cabie, P Pugliese, M-A Valantin, F Bani-Sadr, V Joly, T Ferry, I Poizot-Martin, R Garraffo, G… 
Highly Cited
2015
Highly Cited
2015
Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients
Background Dolutegravir is a powerful, well-tolerated integrase inhibitor with a high genetic barrier to resistance and may thus… 
2014
2014
French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults
These guidelines are part of the French Experts’ recommendations for the management of people living with HIV/AIDS, which were… 
Highly Cited
2014
Highly Cited
2014
Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa…
BACKGROUND The limited access to virological monitoring in developing countries is a major weakness of the current antiretroviral… 
Review
2013
Review
2013
New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents
Research on improved treatment of HIV infection and pre-exposure prophylaxis continues. Poor adherence to treatment is the… 
Highly Cited
2013
Highly Cited
2013
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
Objective:Rilpivirine (RPV) is the latest approved nonnucleoside reverse transcriptase inhibitor (NNRTI). It displays in-vitro… 
2013
2013
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
OBJECTIVES The prevalence of rilpivirine, emtricitabine and tenofovir resistance-associated mutations (RAMs), described in vitro… 
2012
2012
Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects
Background Rilpivirine and efavirenz share metabolic pathways (CYP3A), potentially leading to drug–drug interactions. We report… 
2010
2010
Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems
Many infections favor or are directly implicated with lipid metabolism perturbations and/or increased risk of coronary heart… 
Review
2009
Review
2009
HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
The recent availability of new antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection has… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)